{"id":12738,"date":"2022-03-01T10:35:44","date_gmt":"2022-03-01T09:35:44","guid":{"rendered":"https:\/\/iabnetz.de\/?post_type=publikationen&p=12738"},"modified":"2025-11-14T22:30:51","modified_gmt":"2025-11-14T21:30:51","slug":"modified-constraint-induced-movement-therapy-or-bimanual-occupational-therapy-following-injection-of-botulinum-toxin-a-to-improve-bimanual-performance-in-young-children-with-hemiplegic-cerebral-pa-13","status":"publish","type":"page","link":"https:\/\/relaunch.iabnetz.com\/en\/publikationen\/weitere-veroeffentlichungen\/modified-constraint-induced-movement-therapy-or-bimanual-occupational-therapy-following-injection-of-botulinum-toxin-a-to-improve-bimanual-performance-in-young-children-with-hemiplegic-cerebral-pa-13\/","title":{"rendered":"Patient-centric dose equivalency pilot study of incobotulinumtoxin a (xeomin) vs. abobotulinumtoxin a (dysport) in the treatment of glabellar frown lines: Bank J et al."},"content":{"rendered":"

<\/p>\n

\n
\n
<\/div>\n
\n
\n
\n
\n
\n
Plast Aesthet Res ||\u00a0Vol 2 || Issue 1 || Jan 15, 2015<\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
<\/div>\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
Authors:<\/span><\/div>\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
Jonathan Bank\u00a0 \u00a0<\/span>1<\/span>,
\nNicole A. Phillips\u00a0 \u00a0<\/span>2<\/span>,
\nLaurie A. Casas\u00a0 \u00a0<\/span>1<\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
\u00a0<\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
\u00a0<\/a><\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

 <\/p>\n

\n

Author Details:<\/p>\n

\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
1\u00a0 \u00a0<\/span>Department of Surgery, Section of Plastic and Reconstructive Surgery, University of Chicago Medical Center, Chicago, IL 60026, USA.<\/span><\/div>\n
2\u00a0\u00a0<\/span>Department of Surgery, Division of Plastic Surgery, Brigham and Women\u2019s Hospital, Boston, MA 02115, USA.<\/span><\/div>\n
<\/div>\n
Address for correspondence:<\/span><\/div>\n
\u00a0Dr. Laurie A.\u00a0Casas, Department of Surgery, Section of\u00a0Plastic and Reconstructive Surgery, University of<\/span>Chicago Medical Center, Chicago,\u00a0IL 60026, USA. E-mail:\u00a0lcasas@casas.md<\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n

Please click here!<\/a><\/p>\n<\/div>\n<\/div>\n

<\/p>","protected":false},"excerpt":{"rendered":"

Abstract: Aim: Incobotulinumtoxin A (xeomin) has been proposed as an alternative to abobotulinumtoxinA (dysport) and onabotulinumtoxin A (Botox) in the treatment of glabellar frown lines. A recent
\nstudy is comparing abobotulinumtoxin A and onabotulinumtoxin A revealed equivalent efificacy with a dose conversion ratio of 2.5:1. …<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":30426,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"template-full-width.php","meta":{"_acf_changed":false,"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"class_list":["post-12738","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/relaunch.iabnetz.com\/en\/wp-json\/wp\/v2\/pages\/12738","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/relaunch.iabnetz.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/relaunch.iabnetz.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/relaunch.iabnetz.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/relaunch.iabnetz.com\/en\/wp-json\/wp\/v2\/comments?post=12738"}],"version-history":[{"count":1,"href":"https:\/\/relaunch.iabnetz.com\/en\/wp-json\/wp\/v2\/pages\/12738\/revisions"}],"predecessor-version":[{"id":30668,"href":"https:\/\/relaunch.iabnetz.com\/en\/wp-json\/wp\/v2\/pages\/12738\/revisions\/30668"}],"up":[{"embeddable":true,"href":"https:\/\/relaunch.iabnetz.com\/en\/wp-json\/wp\/v2\/pages\/30426"}],"wp:attachment":[{"href":"https:\/\/relaunch.iabnetz.com\/en\/wp-json\/wp\/v2\/media?parent=12738"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}